NCT02667639View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Healthy
Interventions
BIOLOGICAL

RPH-104

Anti-IL-1 Mab

OTHER

Sodium chloride Sterile Injection 0.9% w/v

Sterile saline solution

Trial Locations (1)

Unknown

ARGEFAR, Izmir

Sponsors

Lead Sponsor

R-Pharm
All Listed Sponsors
collaborator

MonitorCRO

INDUSTRY

lead

R-Pharm

INDUSTRY